Press release
Paiania, 14 April 2025 – Lavipharm S.A. is pleased to announce the establishment of a joint company in partnership with Tikun Olam Europe. This collaboration will introduce telemedicine services via a telemedicine mediation application, in compliance with Article 1 of Ministerial Decision 7686/10.3.25. The primary focus will be on effective pain management based on the approved indications of the respective medications, including final products derived from medical cannabis, thus advancing the modernization of healthcare services.
Telemaque Lavidas, CEO of Lavipharm, remarked: “We are excited to embark on this strategic initiative with Tikun Olam Europe, building upon our previous successful collaboration. The formation of our joint entity in the telemedicine sector represents a pivotal advancement in our mission to provide innovative health solutions tailored to the needs of patients suffering from pain.”
Nikos Beis, CEO of Tikun Olam Europe, added: “We are exceptionally proud to deepen our partnership with Lavipharm through the establishment of this new company that will deliver telemedicine services. This significant step towards modernizing healthcare opens new avenues for patients, enabling easier access to enhanced quality of life.”